Form 4: Veracyte SVP, General Counsel Sells Shares Under 10b5-1 Plan

Annie McGuire, SVP and General Counsel at Veracyte, sold 18,699 shares of common stock at an average price of $44.0226 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Annie McGuire, a Senior Vice President and General Counsel at Veracyte, sold 18,699 shares of the company's common stock on December 4, 2024.
• The sale was executed at a weighted average price of $44.0226 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024.
• Following the sale, Ms. McGuire directly owns 72,869 shares of Veracyte common stock.
• The sale prices ranged from $43.46 to $44.46 per share.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The use of a 10b5-1 trading plan is a common method for corporate insiders to sell shares without raising concerns about insider trading, and is a standard practice across the industry.
• The reported sale is not unusual in terms of volume or price for an executive of a company of Veracyte's size.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on the company's operations or other stakeholders.

Key Dates

Keywords

Veracyte, insider trading, Form 4, Rule 10b5-1, stock sale, Annie McGuire, VCYT